Aims We sought to explore what parents value from their physicians when deciding on treatment for Hypoplastic Left Heart Syndrome (HLHS). We were interested in parental views on the decision-making process, the factors which influence their choices and in the level of physician involvement they desire.

Methods Eight families who had received a diagnosis of HLHS in the last 3 years and had chosen surgical intervention underwent structured interviews lasting between 1–3 hours. Patients were de-identified and results discussed with two Paediatric Cardiologists and a Professor of Bioethics to identify key themes.

Result Parental understanding of HLHS was varied; 6 of the 8 families displayed limited understanding of the long-term complications and quality-of-life issues. All remembered feelings of shock and confusion at the time of diagnosis.

When discussing what motivated their decision to choose surgery the parents all expressed ideas about the ability to give their child hope. When asked how important the following factors were in making their decision, the mean results were: (1: ‘not important at all’; 5: ‘very important’) the doctor’s opinion: 3.6; other people’s opinion: 2.0; religion: 3.8; financial considerations: 1.9; other commitments: 2.9

Seven families felt the decision was entirely up to them. One mother instead said she, her husband and the doctors were “all together” in making the decision. Seven families said the information was presented to them in a neutral manner by the doctor. Seven families felt their doctors were optimistic about their child’s outcome. Three families asked for their doctor’s opinion on treatment whilst five did not, stating it was irrelevant to their decision. Seven families said parents should make decisions regarding treatment of HLHS. One father said the doctors should make the decision, whilst his partner felt it should be both parties. All eight families felt content with their decision and none expressed regrets.

Conclusion Our findings offer valuable insight into the parental experience and indicate that most families with a diagnosis of HLHS felt the decision-making was entirely up to them and that information from doctors was neutral but nonetheless optimistic. Whilst parents wish to remain the final arbiters of the decision, some do value the doctor’s opinion.

Aims To study the demographic, clinical and laboratory findings, diagnoses and outcome of children under 5 years who were admitted with acute liver failure (ALF; INR > 2.0 or INR > 1.5 and encephalopathy) secondary to an underlying inherited metabolic disease (IMD).

Methods A retrospective case note review of children who were admitted between January 2001 to 2012 to a tertiary paediatric liver unit with ALF and a multi-centre review of their long term outcome.

Results A total of 127 children were identified from the database. 36 children (28%; 17 boys; median presenting age 6 weeks, range 1 day–41 months) had an underlying IMD including galactosemia in 17, mitochondrial cytopathy in 7, ornithine transcarbamylase (OTC) deficiency in 4, tyrosinemia type 1 in 4, Niemann-Pick C (NPC) in 3 and congenital disorder of glycosylation type 1 in 1. The remaining aetiologies were: indeterminate in 40 (32%), infectious in 15 (12%), neonatal hemochromatosis in 11 (9%), hemophagocytic syndrome in 8 (6%), drug toxicity in 5 (4%) and other in 10 (8%). Of the 36 children with an IMD consanguinity was present in 16 (44%), developmental delay in 8 (22%), jaundice at presentation in 28 (78%), hepatomegaly in 27 (78%) and encephalopathy in 8 (22%). The median peak (range) INR 4.8 (1.8–15), aspartate transaminase 334umol/L (59–15791) and bilirubin 227umol/L (13–692). Liver biopsy was done in 9 children (25%), neuroimaging in 10 children (28%), bone marrow aspiration in 7 (19%) and muscle biopsy in 5 (14%). 29/36 children with an IMD survived (81%). 4 children with mitochondrial cytopathy (including 1 after transplantation during the postoperative period) and 3 with NPC died. 4 children (1 OTC deficiency; 3 mitochondrial cytopathy) underwent liver transplantation. Follow up data was available for 25 children (mean follow up period, 4 years 3 months) in whom 13 (52%) were identified as having evidence of developmental delay.

Conclusion IMD is a common cause of ALF in children. Indeterminate cases may include undiagnosed metabolic diseases. Survival of children with IMD-related ALF is good, however, long-term developmental outcome is less favourable.